Vaccine maker $NVAX Novavax plans to reduce its total global workforce by about 12% to cut costs. Given the reported results, I understand the move, and I wonder if it will help them dig out of the red when the approval of a new covid vaccine didn't.
Osobní pohled člena komunity, ne investiční doporučení. Pravidla komunity
